Questions on Neurim scope remain post-SPC ruling, say lawyers

The Court of Justice of the European Union’s (CJEU) recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates (SPC) last week has left some big questions unanswered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

CJEU puts further brakes on SPCs

22 March 2019 The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

Americas

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

More on this story

Big Pharma

CJEU puts further brakes on SPCs

22 March 2019 The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

Americas

Neurim prevails against Mylan in suit over insomnia drug

More on this story

Big Pharma

CJEU puts further brakes on SPCs

22 March 2019 The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

Americas

Neurim prevails against Mylan in suit over insomnia drug